Serious adverse events (number) ‐ pegylated interferon‐alpha plus ribavirin versus pegylated interferon‐alpha · people with acute hepatitis C infection
It is very uncertain whether intervention changes serious adverse events (proportion) ‐ pegylated interferon‐alpha… compared with no intervention or control intervention (control) (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether bile acids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · participants with severe alcoholic hepatitis
It is very uncertain whether glucocorticosteroids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with severe alcoholic hepatitis
It is very uncertain whether pentoxifylline changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · alcohol‐related disorders (others)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether pentoxifylline changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · people with primary biliary cholangitis
1 finding from 1 review
Serious adverse events (proportion) · people with primary biliary cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) ( · people with primary biliary cholangitis
It is very uncertain whether D‐Penicillamine changes serious adverse events (proportion) ( compared with no intervention (very low certainty).
1 finding from 1 review